The use of breast cancer subtype classification to predict local and distant recurrence. A review;Intérêt des classifications moléculaires pour prédire la rechute locale et la diffusion métastatique des cancers du sein

Cancer/Radiotherapie

Volumn 12, Issue 6-7, 2008, Pages 577-583

  Belkacemi Y ^a,b   Penault Llorca, F ^c   Gligorov, J ^d,e   Azria, D ^f  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c CLCC Jean Perrin   (France)

^d HÔPITAL TENON   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f CENTRE VAL D AURELLE   (France)

Author keywords

Breast cancer; Breast cancer prognosis; Gene expression profiling; Prediction of response; Subtype classification

Indexed keywords

TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; LYMPH VESSEL; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SHORT SURVEY; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVORS;

EID: 55849092062     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2008.08.272     Document Type: Short Survey

References (36)

1. Ayers M., Symmans W.F., Stec J., Damokosh A.I., Clark E., Hess K., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 (2004) 2284-2293
2. Bartelink H., Horiot J.C., Poortmans P.M., Struikmans H., Van den Bogaert W., Fourquet A., et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25 (2007) 3259-3265
3. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore T.D., Collichio F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007) 2329-2334
4. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295 (2006) 2492-2502
5. Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Elledge R., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
6. Clarke M., Collins R., Darby S., Davies C., Elphinstone P., Evans E., et al., Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
7. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13 (2007) 4429-4434
8. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., Griffith C., et al., IMPACT Trialists. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11 (2005) 951s-958s
9. Gusterson B.A., Gelber R.D., Goldhirsch A., Price K.N., Save-Soderbogh J., Anbazhagan R., et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10 (1992) 1049-1056
10. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24 (2006) 5652-5657
11. Harris J., Morrow M., and Norton L. Malignant tumours of the breast. Cancer: Principles and Practice of Oncology. 5th ed. (1997), Lippincott-Raven, Philadelphia p.1557-616
12. Hess K.R., Anderson K., Symmans W.F., Valero V., Ibrahim N., Mejia J.A., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 (2006) 4236-4244
13. Jansen M.P., Foekens J.A., van Staveren I.L., Dirkzwager-Kiel M.M., Ritstier K., Look M.P., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23 (2005) 732-740
14. Jumppanen M., Gruvberger-Saal S., Kauraniemi P., Tanner M., Bendahl P.O., Lundin M., et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9 (2007) 1-10
15. Kyndi M., Sørensen F.B., Knudsen H., Overgaard M., Nielsen H.M., and Overgaard J. Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 26 (2008) 1419-1426
16. Ma X.J., Salunga R., Tuggle J.T., Gaudet J., Enright E., McQuary P., et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci 100 (2003) 5974-5979
17. Mamounas EP, Tang G, Bryant J, Paik S, Shak S, Costantino J, et al. Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. 28th Annual San Antonio Breast Cancer Symposium Meeting, December 8-11, 2005, San Antonio, TX. Brest Cancer Treat Rev 2005; 94 (Suppl. 1): S16. [abst 29].
18. Moantero A.J., Rouzier R., Lluch A., Theriault R.L., Buzdar A.U., Delaloge S., et al. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer 104 (2005) 229-235
19. Muss H.B. Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status. J Natl Cancer Inst Monogr 30 (2001) 52-55
20. Nguyen P.L., Taghian A.G., Katz M.S., Niemierko A., Abi Raad R.F., Boon W.L., et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26 (2008) 2373-2378
21. Nuyten D.S., Kreike B., Hart A.A., Chi J.T., Sneddon J.B., Wessels L.F., et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8 (2006) R62
22. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
23. Piccart-Gebhart M., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy for HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
24. Pierce L.J. Postmastectomy Radiotherapy. In: Bland K.I., and Copeland E.M. (Eds). The Breast: Comprehensive Management of Benign and Malignant Disorders. 3rd Edition (2004), W. B. Saunders, Philadelphia 1165-1172
25. Rakha E.A., Putti T.C., Abd El-Rehim D.M., Paish C., Green A.R., Powe D.G., et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208 (2006) 495-506
26. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
27. Roylance R., Gorman P., Hanby A., and Tomlinson I. Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. J Pathol 196 (2002) 32-36
28. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ulrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235 (1987) 177-182
29. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100 (2003) 8418-8423
30. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
31. Tabar L., Vitak B., Chen H.H., Prevost T.C., and Duffy S.W. Update of the Swedish Two-County Trial of breast cancer screening: histologic grade-specific and age-specific results. Swiss Surg 5 (1999) 199-204
32. Truong P.T., Lesperance M., Culhaci A., Kader H.A., Speers C.H., and Olivotto I.A. Patient subsets with T1-T2, node-negative breast cancer at high loco-regional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys 62 (2005) 175-182
33. Wallgren A., Bonetti M., Gelber R.D., Goldhirsch A., Castiglione-Gertsch M., Holmberg S.B., et al. International Breast Cancer Study Group Trials I through VII. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21 (2003) 1205-1213
34. Wärnberg F., Nordgren H., Bergkvist L., and Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 85 (2001) 869-874
35. West M., Blanchette C., Dressman H., Huang E., Ishida S., Spang R., et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci 98 (2001) 11462-11467
36. Wright C., Nicholson S., Angus B., Sainsbury J.R., Frandon J., Caims J., et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65 (1992) 118-121